These data established a functional link between EGFR and ErbB3 activity by associating expression of their respective ligands, and suggested that combination of NRG1 with AREG or TGFα may further enrich for KTN3379 anti-tumor activity, particularly when used in combination with cetuximab. Here, AREG is linked to neoplasm.